CN100384878C - 人cd22特异性抗体及其治疗和诊断应用 - Google Patents

人cd22特异性抗体及其治疗和诊断应用 Download PDF

Info

Publication number
CN100384878C
CN100384878C CNB038150433A CN03815043A CN100384878C CN 100384878 C CN100384878 C CN 100384878C CN B038150433 A CNB038150433 A CN B038150433A CN 03815043 A CN03815043 A CN 03815043A CN 100384878 C CN100384878 C CN 100384878C
Authority
CN
China
Prior art keywords
antibody molecule
seq
ser
gly
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB038150433A
Other languages
English (en)
Chinese (zh)
Other versions
CN1662558A (zh
Inventor
A·G·波普勒维尔
S·P·蒂克尔
H·M·拉迪曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9935990&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100384878(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Priority to CN201310021287.1A priority Critical patent/CN103172742B/zh
Publication of CN1662558A publication Critical patent/CN1662558A/zh
Application granted granted Critical
Publication of CN100384878C publication Critical patent/CN100384878C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNB038150433A 2002-05-02 2003-05-02 人cd22特异性抗体及其治疗和诊断应用 Expired - Lifetime CN100384878C (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310021287.1A CN103172742B (zh) 2002-05-02 2003-05-02 人cd22特异性抗体及其治疗和诊断应用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0210121.0 2002-05-02
GBGB0210121.0A GB0210121D0 (en) 2002-05-02 2002-05-02 Biological products

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN2007100852904A Division CN101134779B (zh) 2002-05-02 2003-05-02 人cd22特异性抗体及其治疗和诊断应用
CN201310021287.1A Division CN103172742B (zh) 2002-05-02 2003-05-02 人cd22特异性抗体及其治疗和诊断应用

Publications (2)

Publication Number Publication Date
CN1662558A CN1662558A (zh) 2005-08-31
CN100384878C true CN100384878C (zh) 2008-04-30

Family

ID=9935990

Family Applications (3)

Application Number Title Priority Date Filing Date
CNB038150433A Expired - Lifetime CN100384878C (zh) 2002-05-02 2003-05-02 人cd22特异性抗体及其治疗和诊断应用
CN201310021287.1A Expired - Lifetime CN103172742B (zh) 2002-05-02 2003-05-02 人cd22特异性抗体及其治疗和诊断应用
CN2007100852904A Expired - Lifetime CN101134779B (zh) 2002-05-02 2003-05-02 人cd22特异性抗体及其治疗和诊断应用

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201310021287.1A Expired - Lifetime CN103172742B (zh) 2002-05-02 2003-05-02 人cd22特异性抗体及其治疗和诊断应用
CN2007100852904A Expired - Lifetime CN101134779B (zh) 2002-05-02 2003-05-02 人cd22特异性抗体及其治疗和诊断应用

Country Status (34)

Country Link
US (8) US7355011B2 (cg-RX-API-DMAC7.html)
EP (1) EP1504035B9 (cg-RX-API-DMAC7.html)
JP (3) JP4486494B2 (cg-RX-API-DMAC7.html)
KR (3) KR101386376B1 (cg-RX-API-DMAC7.html)
CN (3) CN100384878C (cg-RX-API-DMAC7.html)
AT (1) ATE462729T3 (cg-RX-API-DMAC7.html)
AU (1) AU2003223007C1 (cg-RX-API-DMAC7.html)
BE (1) BE2017C068I2 (cg-RX-API-DMAC7.html)
CA (1) CA2484420C (cg-RX-API-DMAC7.html)
CO (1) CO5631451A2 (cg-RX-API-DMAC7.html)
CY (3) CY1110134T1 (cg-RX-API-DMAC7.html)
DE (1) DE60331910D1 (cg-RX-API-DMAC7.html)
DK (1) DK1504035T6 (cg-RX-API-DMAC7.html)
EC (1) ECSP045470A (cg-RX-API-DMAC7.html)
ES (1) ES2341708T7 (cg-RX-API-DMAC7.html)
FR (1) FR17C1062I2 (cg-RX-API-DMAC7.html)
GB (1) GB0210121D0 (cg-RX-API-DMAC7.html)
HU (2) HUS1700056I1 (cg-RX-API-DMAC7.html)
IL (1) IL164923A (cg-RX-API-DMAC7.html)
LT (2) LTC1504035I2 (cg-RX-API-DMAC7.html)
LU (2) LUC00057I2 (cg-RX-API-DMAC7.html)
MX (1) MXPA04010787A (cg-RX-API-DMAC7.html)
NL (1) NL300920I2 (cg-RX-API-DMAC7.html)
NO (3) NO336201B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ536757A (cg-RX-API-DMAC7.html)
PL (1) PL218433B1 (cg-RX-API-DMAC7.html)
PT (1) PT1504035E (cg-RX-API-DMAC7.html)
RU (1) RU2342401C2 (cg-RX-API-DMAC7.html)
SG (1) SG161744A1 (cg-RX-API-DMAC7.html)
SI (1) SI1504035T1 (cg-RX-API-DMAC7.html)
TW (1) TWI324161B (cg-RX-API-DMAC7.html)
UA (1) UA92580C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003093320A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200408851B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107849140A (zh) * 2015-07-16 2018-03-27 Ucb生物制药私人有限公司 结合cd22的抗体分子

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2342929T3 (es) * 2001-09-26 2010-07-19 The Government of the United States of America as represented by the Secretary of Health and Human Anticuerpos anti-cd22 con afinidad aumentada por las celulas leucemicas que expresan cd22.
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
DE60334364D1 (de) 2002-02-21 2010-11-11 Univ California Behandlungsverfahren unter verwendung von anti-cd22-antikörpern
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
SG165158A1 (en) * 2002-05-02 2010-10-28 Wyeth Corp Calicheamicin derivative-carrier conjugates
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GT200500283A (es) * 2004-10-08 2006-05-08 Inmunoterapia de desordenes autoinmunes
MX2007015476A (es) 2005-06-14 2008-02-25 Amgen Inc Formulaciones de proteina autoamortiguadoras.
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
CA2644906C (en) * 2006-03-06 2016-05-10 Medimmune, Inc. Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2007103469A2 (en) * 2006-03-06 2007-09-13 Aeres Biomedical Ltd. Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
PT2032606E (pt) * 2006-05-30 2014-02-05 Genentech Inc Anticorpos e imunoconjugados e respetivas utilizações
CA2671457C (en) 2006-12-01 2017-09-26 Medarex, Inc. Human antibodies that bind cd22 and uses thereof
WO2009124109A1 (en) 2008-04-04 2009-10-08 The Government Of The U.S. A. As Represented By The Secretary Of The Dept. Of Health &Human Services Human monoclonal antibodies specific for cd22
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
KR20120104517A (ko) 2009-09-03 2012-09-21 제넨테크, 인크. 류마티스 관절염의 치료, 진단 및 모니터링 방법
AU2012205301B2 (en) 2011-01-14 2017-01-05 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
MX353143B (es) 2011-02-28 2017-12-20 Genentech Inc Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b.
WO2013163519A1 (en) * 2012-04-26 2013-10-31 Jay Short Anti-cd22 antibodies
MX359555B (es) 2012-07-03 2018-10-02 Univ Washington Anticuerpos para tau.
AU2013290424B2 (en) 2012-07-19 2018-01-25 Redwood Bioscience, Inc. Antibody specific for CD22 and methods of use thereof
US10072078B2 (en) * 2012-10-24 2018-09-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services M971 chimeric antigen receptors
CN103214578B (zh) * 2013-05-10 2014-05-28 北京东方百泰生物科技有限公司 一种新型的人源化抗cd22抗体
BR112016010051A2 (pt) 2013-11-04 2017-12-05 Pfizer ?conjugados de anticorpo-fármaco anti-efna4?
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
HRP20220893T1 (hr) * 2015-04-08 2022-10-14 Novartis Ag Cd20 terapije, cd22 terapije, i kombinirane terapije sa stanicom koja eksprimira cd19 kimerni antigenski receptor
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
US12102689B2 (en) 2015-11-09 2024-10-01 R.P. Scherer Technologies, Llc Anti-CD22 antibody-maytansine conjugates and methods of use thereof
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
US11208632B2 (en) 2016-04-26 2021-12-28 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
GB201610512D0 (en) * 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
CA3040899A1 (en) 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
CA3095595A1 (en) * 2018-03-30 2019-10-03 Eureka Therapeutics, Inc. Constructs targeting cd22 and uses thereof
CN115335405B (zh) * 2020-04-02 2024-02-23 南京驯鹿生物技术股份有限公司 全人源抗人cd22的嵌合抗原受体及其应用
CN114106177B (zh) * 2020-08-27 2024-04-09 深圳市菲鹏生物治疗股份有限公司 Cd22抗体及其应用
WO2022262783A1 (zh) * 2021-06-16 2022-12-22 西安宇繁生物科技有限责任公司 抗cd22的全人源抗体或其抗原结合片段及其制备方法和应用
US20250129180A1 (en) * 2021-08-27 2025-04-24 Peptron, Inc. Novel anti-muc1 antibody and use thereof
CN119751680A (zh) * 2021-12-06 2025-04-04 重庆精准生物技术有限公司 靶向cd22的抗原结合片段和单链抗体及其应用
WO2024102693A2 (en) 2022-11-07 2024-05-16 Xencor, Inc. Il-18-fc fusion proteins

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015683A1 (en) * 1991-03-06 1992-09-17 MERCK Patent Gesellschaft mit beschränkter Haftung Humanized and chimeric monoclonal antibodies
WO1994029451A2 (en) * 1993-06-16 1994-12-22 Celltech Limited Humanised antibodies
WO1996004925A1 (en) * 1994-08-12 1996-02-22 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
WO2001094585A1 (en) * 2000-06-06 2001-12-13 Celltech R & D Limited Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957362A (en) * 1972-10-02 1976-05-18 Corneal Sciences, Inc. Hydrogels and articles made therefrom
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5134075A (en) * 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ES2164045T3 (es) * 1990-06-27 2002-02-16 Univ Princeton Sondas para la deteccion de p53 mutante.
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5714340A (en) * 1992-12-22 1998-02-03 Johnson & Johnson Clinical Diagnostics, Inc. Immunoassay elements having a receptor zone
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
KR100367948B1 (ko) 1994-01-25 2003-07-12 엘란 파마슈티칼스, 인크. 백혈구부착분자vla-4에대한인체화된항체
CA2196797C (en) 1994-08-12 2000-10-10 Donna M. Shattuck-Eidens In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) * 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
WO1998019704A1 (en) * 1996-11-01 1998-05-14 Smithkline Beecham Corporation Human monoclonal antibodies
US20020141990A1 (en) * 1996-11-01 2002-10-03 Smithkline Beecham Corporation Anti-RSV human monoclonal antibodies
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
AU740904B2 (en) 1997-03-20 2001-11-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
CA2635352C (en) 1997-06-13 2012-09-11 Genentech, Inc. Stabilized antibody formulation
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
KR100345463B1 (ko) * 1998-11-19 2003-01-08 주)녹십자 B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법
DE05075555T1 (de) * 1999-06-09 2007-02-08 Immunomedics, Inc. Immuntherapie von Autoimmunerkrankungen durch die Verwendung von B-Zell-spezifischen Antikörpern
JP2003511697A (ja) * 1999-10-12 2003-03-25 コンネクス・ゲゼルシャフト・ツーア・オプティミエルング・フォン・フォルシュング・ウント・エントヴィックルング・エムベーハー 便中の酸耐性微生物を検出するためのイムノクロマトグラフィー迅速試験
AU2001264612C1 (en) * 1999-11-08 2007-11-22 Biogen Idec Inc. Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
CN1205479C (zh) * 2000-10-31 2005-06-08 杨梦甦 免疫学诊断蛋白芯片制备方法
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
SG165158A1 (en) * 2002-05-02 2010-10-28 Wyeth Corp Calicheamicin derivative-carrier conjugates
WO2007103469A2 (en) * 2006-03-06 2007-09-13 Aeres Biomedical Ltd. Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015683A1 (en) * 1991-03-06 1992-09-17 MERCK Patent Gesellschaft mit beschränkter Haftung Humanized and chimeric monoclonal antibodies
WO1994029451A2 (en) * 1993-06-16 1994-12-22 Celltech Limited Humanised antibodies
WO1996004925A1 (en) * 1994-08-12 1996-02-22 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
WO2001094585A1 (en) * 2000-06-06 2001-12-13 Celltech R & D Limited Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CONSTRUCTION AND CHARACTERIZATIONOFAHUMANIZED, INTERNALIZING,B-CELL(CD22)-SPECIFIC,LEUKEMIA/LYMPHOMAANTIBODY,LL2. SHUI-ON LEUNG et al.MEOLECULAR IMMUNOLOGY,Vol.32 No.17/18. 1995 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107849140A (zh) * 2015-07-16 2018-03-27 Ucb生物制药私人有限公司 结合cd22的抗体分子

Also Published As

Publication number Publication date
CA2484420A1 (en) 2003-11-13
FR17C1062I1 (cg-RX-API-DMAC7.html) 2018-02-16
CY2017046I2 (el) 2018-12-12
LUC00058I1 (cg-RX-API-DMAC7.html) 2017-12-27
KR101238970B1 (ko) 2013-03-04
CN101134779B (zh) 2013-03-13
JP2013230158A (ja) 2013-11-14
NO20044742L (no) 2004-12-22
ZA200408851B (en) 2006-01-25
HK1186479A1 (zh) 2014-03-14
LUC00057I1 (cg-RX-API-DMAC7.html) 2017-12-27
IL164923A0 (en) 2005-12-18
US8895714B2 (en) 2014-11-25
RU2342401C2 (ru) 2008-12-27
JP2010022372A (ja) 2010-02-04
EP1504035B1 (en) 2010-03-31
HUS1700055I1 (hu) 2018-07-30
US20030235869A1 (en) 2003-12-25
WO2003093320A2 (en) 2003-11-13
CY2017046I1 (el) 2018-12-12
CN101134779A (zh) 2008-03-05
PL218433B1 (pl) 2014-12-31
FR17C1062I2 (fr) 2020-05-29
TWI324161B (en) 2010-05-01
CO5631451A2 (es) 2006-04-28
CY2017045I1 (el) 2019-11-27
JP5377173B2 (ja) 2013-12-25
ES2341708T7 (es) 2018-04-11
LUC00058I2 (cg-RX-API-DMAC7.html) 2018-02-26
CA2484420C (en) 2014-09-16
AU2003223007C1 (en) 2019-08-08
CN103172742A (zh) 2013-06-26
IL164923A (en) 2012-03-29
LTPA2017043I1 (lt) 2018-01-10
RU2004135103A (ru) 2005-10-27
PL373277A1 (en) 2005-08-22
EP1504035B3 (en) 2017-12-20
UA92580C2 (ru) 2010-11-25
JP4486494B2 (ja) 2010-06-23
KR20120127513A (ko) 2012-11-21
NO336201B3 (no) 2015-06-15
NO2017069I1 (no) 2017-12-21
US7355011B2 (en) 2008-04-08
KR20050025167A (ko) 2005-03-11
US20160326247A1 (en) 2016-11-10
KR101386376B1 (ko) 2014-04-16
US20170145114A1 (en) 2017-05-25
KR101156796B1 (ko) 2012-06-21
JP2006506955A (ja) 2006-03-02
CY1110134T1 (el) 2015-01-14
DK1504035T6 (en) 2018-03-12
EP1504035A2 (en) 2005-02-09
CN103172742B (zh) 2016-05-11
WO2003093320A3 (en) 2004-02-05
NO2017068I1 (no) 2017-12-21
US20100021995A1 (en) 2010-01-28
LUC00057I2 (cg-RX-API-DMAC7.html) 2018-02-26
ATE462729T3 (de) 2010-04-15
HUS1700056I1 (hu) 2018-07-30
LTC1504035I2 (lt) 2022-04-11
US7919606B2 (en) 2011-04-05
GB0210121D0 (en) 2002-06-12
NO336201B1 (no) 2015-06-15
SI1504035T1 (sl) 2010-07-30
US20120302739A1 (en) 2012-11-29
SG161744A1 (en) 2010-06-29
CY2017045I2 (el) 2019-11-27
NZ536757A (en) 2006-06-30
JP5920934B2 (ja) 2016-05-18
CN1662558A (zh) 2005-08-31
US20110165659A1 (en) 2011-07-07
AU2003223007B2 (en) 2009-07-16
ECSP045470A (es) 2005-01-28
DE60331910D1 (de) 2010-05-12
PT1504035E (pt) 2010-06-07
US20210371547A1 (en) 2021-12-02
BE2017C068I2 (cg-RX-API-DMAC7.html) 2022-08-09
EP1504035B9 (en) 2018-10-17
US20070059307A1 (en) 2007-03-15
ES2341708T3 (es) 2010-06-25
LTPA2017044I1 (lt) 2018-01-10
HK1071762A1 (en) 2005-07-29
NL300920I2 (nl) 2021-04-15
TW200307690A (en) 2003-12-16
AU2003223007A1 (en) 2003-11-17
DK1504035T3 (da) 2010-06-07
MXPA04010787A (es) 2005-03-07
NL300920I1 (cg-RX-API-DMAC7.html) 2018-01-03
EP1504035B8 (en) 2018-02-28
KR20110004463A (ko) 2011-01-13

Similar Documents

Publication Publication Date Title
CN100384878C (zh) 人cd22特异性抗体及其治疗和诊断应用
HK1186479B (en) Antibodies specific for human cd22 and their therapeutic and diagnostic uses
BRPI0309730B1 (pt) Molécula de anticorpo possuindo especificidade para cd22 humana, sequência de dna, vetor de expressão ou clonagem, célula hospedeira, uso da molécula de anticorpo ou da sequência de dna, composição diagnóstica ou terapêutica, processo para a produção de uma molécula de anticorpo, processo para a preparação de uma composição diagnóstica ou terapêutica
HK1071762B (en) Antibodies specific for human cd22 and their therapeutic and diagnostic uses

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: UCB PHARMACY CO.,LTD.

Free format text: FORMER OWNER: CELLTECH R. + D. LTD.

Effective date: 20091218

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20091218

Address after: Brussels

Patentee after: UCB BIOPHARMA SPRL

Address before: Burke County, England

Patentee before: CELLTECH R&D LTD.

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20080430